Table 1.
Study population characteristics (n = 39) of Crohn’s disease patients with ‘normal’ (< 200 mg/kg) and increased (> 200 mg/kg) fecal calprotectin levels.
Table 2.
Median (IQR) of serum levels of all detected molecules (pg/mL) in Crohn’s disease patients with ‘normal’ (< 200 mg/kg) and increased (> 200 mg/kg) fecal calprotectin levels.
Fig 1.
Distribution of serum biomarker levels in patients with normal (blue, < 200 mg/kg) and increased (red, > 200 mg/kg) fecal calprotectin levels, shown in boxplots.
(A) Serum CRP levels (pg/mL). (B) Serum IFN-γ levels (pg/mL). *P < 0.05; **P < 0.01.
Fig 2.
Distribution of serum biomarker levels in patients with normal (blue, < 200 mg/kg) and increased (red, > 200 mg/kg) fecal calprotectin levels, shown in boxplots.
(A) Serum IL-6 levels (pg/mL). (B) Serum IL-17A levels (pg/mL). (C) Serum TNF-β levels (pg/mL). (D) Serum SAA levels (pg/mL). *P < 0.05; **P < 0.01.
Table 3.
Correlations of fecal calprotectin levels (mg/kg) with serum levels of all detected molecules (pg/mL) in patients with Crohn’s disease.